PTV外剂量能否影响接受立体定向体部放疗的I期肺癌患者远处转移风险
该研究纳入2家机构217例接受SBRT的I期非小细胞肺癌患者,分析PTV外侧不同大小区域的辐射剂量与远处转移、局部区域控制及放射性肺炎的相关性。结果显示PTV外30mm壳形区域平均剂量与远处转移风险显著相关,2年远处转移率在高剂量组为5%、低剂量组为60%,风险比24.2(95%CI 10.7,54.4;P<10-5),未发现与局部区域控制或放射性肺炎的相关性。
要点
- PTV外30mm壳形区域平均剂量与远处转移风险相关,高剂量组2年远处转移率5% vs 低剂量组60%。
- 该区域平均剂量预测远处转移的AUC为0.82,风险比24.2(95%CI 10.7,54.4;P<10-5)。
- 未发现任何因素与局部区域控制或放射性肺炎相关。
核心结论
- 作者认为,PTV邻近区域接受的剂量对接受SBRT的I期非小细胞肺癌患者远处转移风险有显著影响。
- 作者指出,若这些结果被独立证实,尤其当治疗计划导致从PTV向外延伸的陡峭剂量梯度时应谨慎。
研究设计与样本
- 研究纳入2家机构共217例接受SBRT的I期非小细胞肺癌患者。
- 分析临床与剂量学因素,计算PTV外侧不同大小区域的剂量(转换为EQD2),并估计AUC及比值比,行Kaplan-Meier分析。
主要发现
- 中位随访24个月,37例(17%)患者发生远处转移。
- PTV外30mm厚壳形区域平均剂量的AUC为0.82。
- 治疗完成2年后,该区域平均剂量高于20.8 Gy2的患者远处转移率为5%,低于20.8 Gy2的患者为60%。
- Kaplan-Meier分析风险比为24.2(95%CI 10.7,54.4;P<10-5)。
- 未发现任何因素与局部区域控制或放射性肺炎相关。
局限性
- 作者指出若这些结果被独立证实,尤其当治疗计划导致从PTV向外延伸的陡峭剂量梯度时应谨慎,原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: In an era where little is known about the "abscopal" (out-of-the-field) effects of lung SBRT, we investigated correlations between the radiation dose proximally outside the PTV and the risk of cancer recurrence after SBRT in patients with primary stage I non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: This study included 217 stage I NSCLC patients across 2 institutions who received SBRT. Correlations between clinical and dosimetric factors were investigated. The clinical factors considered were distant metastasis (DM), loco-regional control (LRC) and radiation pneumonitis (RP). The dose (converted to EQD2) delivered to regions of varying size directly outside of the PTV was computed. For each feature, area under the curve (AUC) and odds ratios with respect to the outcome parameters DM, LRC and RP were estimated; Kaplan-Meier (KM) analysis was also performed. RESULTS: Thirty-seven (17%) patients developed DM after a median follow-up of 24 months. It was found that the mean dose delivered to a shell-shaped region of thickness 30 mm outside the PTV had an AUC of 0.82. Two years after treatment completion, the rate of DM in patients where the mean dose delivered to this region was higher than 20.8 Gy2 was 5% compared to 60% in those who received a dose lower than 20.8 Gy2. KM analysis resulted in a hazard ratio of 24.2 (95% CI: 10.7, 54.4); p < 10-5. No correlations were found between any factor and either LRC or RP. CONCLUSIONS: The results of this study suggest that the dose received by the region close to the PTV has a significant impact on the risk of distant metastases in stage I NSCLC patients treated with SBRT. If these results are independently confirmed, caution should be taken, particularly when a treatment plan results in a steep dose gradient extending outwards from the PTV.
引用
- Diamant A, Chatterjee A, Faria S, et al. Can dose outside the PTV influence the risk of distant metastases in stage I lung cancer patients treated with stereotactic body radiotherapy (SBRT)? Radiother Oncol. 2018. PMID: 29801721. doi:10.1016/j.radonc.2018.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。